CLINICAL_TRIALS ClinicalTrials.gov record update

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03610490
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:35.845435+00:00
Published At: 2025-04-17T00:00:00+00:00
Record Updated At: 2025-04-17
Results Posted At: 2025-04-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Malignant Solid Neoplasm", "Metastatic Colorectal Adenocarcinoma", "Metastatic Ovarian Carcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Platinum-Resistant Ovarian Carcinoma", "Recurrent High Grade Ovarian Serous Adenocarcinoma", "Recurrent Ovarian Carcinosarcoma", "Refractory Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-04-17"
protocolSection.identificationModule.nctId: "NCT03610490"
protocolSection.identificationModule.officialTitle: "Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-04-17"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.